Cipla's oncology drug Abraxane will be launched from its Goa facility while respiratory drug Advair will be rolled out from ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth.

Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after ...

IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index fell 20.60 points or 0.09% to 23,184.75.

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Although Dr Reddy's Laboratories' Q3 earnings slightly exceeded analysts' expectations, the main point of concern was the ...

Shares of Dr Reddy's Laboratories dropped 6% in early trade on Friday, a day after the company reported a third-quarter ...

Extending losses for the second session, Dr Reddy’s shares dropped 6.65% to hit a low of ₹1,203.60 on the BSE as investors weighed weak Q3 results.

Indian shares were subdued on Friday after U.S. President Donald Trump reiterated his firm stance on tariffs. At the World Economic ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.